Table 2.

Summary of meta-analyses of pretransplantation IFN treatment in HCV+ dialysis patientsa

StudyPatientsTreatmentPooled SVR Rate (95% CI)Discontinuation Rate
Fabrizi et al., 2003 (77)269 patients from 14 studiesIFN 3 MU thrice weekly in five trials; heterogeneous with other factorsOverall 39% (25 to 56%)Dropout rate 17%
Russo et al., 2003 (78)213 patients from 11 studiesIFN 3 MU thrice weekly in eight studies; higher dosages in three studiesOverall 33% (21 to 51%)Dropout rate 29.6%
Genotype 1 only: 26% (15 to 37%)
  • a SVR, sustained virologic response.